This NIH SBIR U44 cooperative agreement is for the preclinical development of innovative therapeutics aimed at fundamental aging mechanisms like inflammation, cell senescence, and proteostasis. This grant supports translating a wide array of potential geroscience-based therapies, including novel compounds such as senolytics, biologics, and stem/progenitor cell-based approaches. It also covers repositioning or repurposing existing FDA-approved drugs for treating and preventing aging-related clinical conditions. Eligible research activities include target validation, optimizing lead compounds, pharmacokinetic studies, and crucial preclinical safety and toxicology assessments. The ultimate purpose of this grant is to advance promising treatments that combat the biological processes of aging.
Opportunity ID: 327838
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-AG-21-026 |
| Funding Opportunity Title: | Preclinical Development of Novel Therapeutics Targeting Aging Mechanisms (SBIR U44 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.866 — Aging Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jun 25, 2020 |
| Last Updated Date: | Jun 25, 2020 |
| Original Closing Date for Applications: | Nov 10, 2020 |
| Current Closing Date for Applications: | Nov 10, 2020 |
| Archive Date: | Dec 16, 2020 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. see the funding announcement for eligibility details |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) utilizes the SBIR cooperative agreement (U44) activity code to support the preclinical development of emerging therapeutics targeting fundamental mechanisms of aging (e.g., inflammation, cell senescence, proteostasis). This includes the translation of a broad range of potential geroscience-based therapies, such as new classes of compounds (e.g., senolytics), biologics, stem/progenitor cell-based therapies, repositioning of existing investigational drugs, and repurposing of Food and Drug Administration (FDA)-approved drugs for the treatment and prevention of clinical conditions related to aging and common in the aged. Examples of translational research activities eligible under this FOA include target validation, optimization of lead compounds, pharmacokinetics and drug disposition studies, as well as preclinical safety/toxicology studies. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-026.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or after May 25, 2020 | PKG00262315 | Oct 10, 2020 | Nov 10, 2020 | View |
Package 1
Mandatory forms
327838 RR_SF424_2_0-2.0.pdf
327838 PHS398_CoverPageSupplement_5_0-5.0.pdf
327838 RR_OtherProjectInfo_1_4-1.4.pdf
327838 PerformanceSite_2_0-2.0.pdf
327838 RR_KeyPersonExpanded_2_0-2.0.pdf
327838 RR_Budget_1_4-1.4.pdf
327838 PHS398_ResearchPlan_4_0-4.0.pdf
327838 SBIR_STTR_Information_1_3-1.3.pdf
327838 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
327838 RR_SubawardBudget30_1_4-1.4.pdf
327838 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
